ProCE Banner Series

Targeting CD38 and BCMA in Myeloma: Evidence and Enhanced Outcomes With Innovative Therapies

Join our live webinar to gain expert insights on the use of CD38- and BCMA-targeted agents in the management of newly diagnosed and relapsed/refractory multiple myeloma, including a discussion on barriers to health equity for patients. Register now for this comprehensive and interactive session. 

  AMA
Who Should Attend

This program is intended for oncologists and other healthcare professionals treating patients with MM.

All Events

Targeting CD38 and BCMA in Myeloma: Evidence and Enhanced Outcomes With Innovative Therapies

Upcoming Events

July

24

2024

6:30 PM - 8:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Craig Emmitt Cole, MD

Hematologist
Karmanos Cancer Institute
Multiple Myeloma/Amyloidosis Multidisciplinary Program
Clinical Associate Professor, Wayne State University School of Medicine
Clinical Associate Professor, Michigan State University College of Human Medicine
Detroit, Michigan

ProCE Banner Faculty
Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Lead, Cancer Immunology and Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

ProCE Banner Faculty
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Topics

Targeting CD38 and BCMA in Myeloma: Evidence and Enhanced Outcomes With Innovative Therapies

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge, confidence, and competence in using evidence-based and guideline-directed best practices in caring for patients with MM.

Target Audience
This program is intended for oncologists and other healthcare professionals treating patients with MM.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the distinctive mechanisms of action (MOA) and weigh the safety/efficacy evidence that justifies the application of CD38 and BCMA-targeting antibodies, CAR-T therapy, and other novel compounds in diverse multiple myeloma treatment scenarios

  • Interpret patient-specific prognostic data to formulate upfront and sequential treatment strategies employing innovative antibody and immunotherapy platforms, keeping safety considerations paramount

  • Educate and counsel patients on the hands-on facets of multiple myeloma care with antibody and immunotherapy platforms, emphasizing dosing and scheduling

  • Apply recommended strategies for effectively mitigating and managing the toxicities linked to CD38 and BCMA-targeting antibodies, CAR-T therapy, and other innovative compounds to optimize patient safety and treatment outcomes

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport
662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Sanofi.